Treatments · Oculoplastics · Orbital surgery · Updated May 2026
Private orbital decompression for thyroid eye disease, UK 2026
Orbital decompression is a consultant-led oculoplastic and skull-base operation that creates additional space for the proptotic eye in thyroid eye disease (Graves' orbitopathy) by removing one, two or three of the bony walls of the orbit and, where indicated, a controlled volume of intraconal orbital fat. The procedure is used for sight-threatening dysthyroid optic neuropathy as an urgent intervention and, in the inactive fibrotic phase, for severe exposure keratopathy, disabling proptosis, chronic globe subluxation and disfiguring exophthalmos refractory to medical therapy.
Modern UK practice in 2026 uses a balanced two-wall medial-plus-lateral approach in most rehabilitative cases, a three-wall approach with fat removal for very high proptosis and an endoscopic transethmoidal medial wall approach for dysthyroid optic neuropathy at the orbital apex. UK 2026 projected private self-pay is approximately GBP 7,500-12,000 unilateral, GBP 12,000-18,000 bilateral two-wall and GBP 15,000-22,000 bilateral three-wall, depending on approach and consultant. Orbital decompression sits as the first step of the established three-stage rehabilitative sequence: orbital decompression first, then strabismus surgery, then eyelid surgery.
Fast answer: private orbital decompression for thyroid eye disease in the UK in 2026
Typical cost
GBP 7,500-12,000 unilateral, GBP 12,000-18,000 bilateral two-wall and GBP 15,000-22,000 bilateral three-wall self-pay, inclusive of consultant assessment, CT or MRI imaging, theatre, prosthetic implants where used, inpatient stay and follow-up.
What it does
Removes selected bony walls of the orbit (medial, inferior, lateral) and, where indicated, intraconal orbital fat, to create additional volume for the swollen extraocular muscles and orbital tissues and to relieve proptosis or apical optic nerve compression.
Procedure time and stay
Approximately 90-180 minutes per side under general anaesthesia. Typical inpatient stay is 1-2 nights for bilateral decompression with planned overnight observation of vision, pupils and orbital pressure.
Proptosis reduction
A balanced two-wall decompression typically reduces proptosis by approximately 3-5 mm per side; a three-wall decompression with fat removal can achieve 5-7 mm or more, calibrated against the preoperative Hertel exophthalmometer reading.
What is orbital decompression?
Thyroid eye disease (TED), also known as Graves' orbitopathy, is an autoimmune inflammatory disorder of the orbit that causes enlargement of the extraocular muscles and expansion of the orbital fat compartment. The resulting increase in orbital volume within the fixed bony orbit drives proptosis (forward displacement of the eye), eyelid retraction, exposure of the cornea, restricted eye movement with diplopia and, in the most serious form, apical compression of the optic nerve (dysthyroid optic neuropathy) with sight loss. Orbital decompression is the surgical answer to a volume problem: removing bony walls of the orbit (and sometimes orbital fat) creates additional space and allows the orbital contents to expand into the adjacent paranasal sinuses or temporal fossa, reducing both proptosis and apical pressure.
Modern UK practice in 2026 uses a tailored approach: a balanced two-wall medial-plus-lateral decompression is the workhorse for rehabilitative cases in the inactive fibrotic phase, calibrated to deliver symmetric proptosis reduction without inducing new diplopia. An endoscopic transethmoidal medial wall decompression with apical bone removal is the preferred urgent approach for sight-threatening dysthyroid optic neuropathy. A three-wall decompression with selective fat removal is reserved for very high proptosis or chronic globe subluxation. Orbital decompression sits within the wider oculoplastics service and is the first step of the established three-stage rehabilitative sequence: orbital decompression first, then strabismus surgery, then eyelid surgery (see adult squint surgery and blepharoplasty).
UK 2026 private orbital decompression cost
Private orbital decompression is priced per side and per approach and where available includes the consultant oculoplastic and skull-base assessment, multidisciplinary planning, dedicated orbital CT and (where indicated) MRI, anaesthetic fees, theatre, prosthetic plates or mesh if used in a lateral wall reconstruction, the inpatient stay and a 12-month follow-up programme aligned with the staged rehabilitative pathway.
| Procedure | Typical UK 2026 cost |
|---|---|
| Unilateral two-wall (balanced medial + lateral) orbital decompression | GBP 7,500-12,000 |
| Bilateral two-wall (balanced medial + lateral) orbital decompression | GBP 12,000-18,000 |
| Bilateral three-wall orbital decompression with fat removal | GBP 15,000-22,000 |
| Urgent endoscopic medial wall decompression for dysthyroid optic neuropathy | Bespoke quote on a same-week pathway |
| Subsequent strabismus surgery (post-decompression diplopia) | See the adult squint surgery price page |
See the oculoplastics price list, the wider prices index and the related Tepezza (teprotumumab) infusion cost for the medical alternative in active TED. Stage payment via finance is available where the indication is met.
What is included in your orbital decompression package
Consultant oculoplastic assessment
A consultant-led oculoplastic and orbital workup - see what to expect at your consultation - including thyroid status, Clinical Activity Score (CAS), Hertel exophthalmometry, visual acuity, colour vision, RAPD assessment, visual fields, ocular motility and eyelid measurements.
Multidisciplinary planning
A multidisciplinary planning discussion with the consultant oculoplastic surgeon, endocrine team, ENT skull-base team (for endoscopic medial decompression) and the strabismus surgeon, with sequencing of decompression, squint and eyelid surgery.
Dedicated orbital imaging
Dedicated orbital CT (and MRI where indicated) for surgical planning, mapping the medial wall, ethmoid sinus, orbital apex, lateral wall and skull base anatomy and quantifying extraocular muscle enlargement.
Surgery, prosthetic implants and inpatient stay
The decompression itself under general anaesthesia in a CQC-regulated UK private hospital, with prosthetic plates or mesh if used in lateral wall reconstruction, the 1-2 night inpatient stay and overnight orbital observation.
Structured 12-month follow-up
Day 1, week 1-2, week 6, 3-month, 6-month and 12-month consultant reviews with refraction, Hertel exophthalmometry, ocular motility and visual field testing, with a pre-planned escalation path to strabismus and eyelid surgery where required.
Direct surgeon continuity
Direct continuity with your operating consultant oculoplastic surgeon, with an in-house pathway to adult squint surgery, ptosis and blepharoplasty for the subsequent rehabilitative stages.
What does the evidence say about orbital decompression?
Orbital decompression is one of the best-established interventions in oculoplastic and orbital surgery, with a multi-decade evidence base from European Group on Graves' Orbitopathy (EUGOGO) and Royal College of Ophthalmologists publications, prospective UK and international cohort studies and randomised comparative work on approach selection. EUGOGO consensus statements set out the staged rehabilitative sequence (decompression first, then strabismus, then eyelid surgery) and the urgent indication for decompression in sight-threatening dysthyroid optic neuropathy when high-dose intravenous glucocorticoid therapy has failed to restore visual function within an appropriate timeframe.
Reported proptosis reduction is approximately 3-5 mm per side for a balanced two-wall medial + lateral decompression and 5-7 mm or more for a three-wall decompression with fat removal, calibrated against the preoperative Hertel exophthalmometer reading. Vision and visual fields recover in the great majority of dysthyroid optic neuropathy cases when decompression is performed early. The most clinically significant late effect is new or worsened postoperative diplopia, reported in approximately 15-30 percent of cases overall, and lower in balanced two-wall decompression than in older isolated inferomedial approaches. New-onset diplopia is managed within the planned rehabilitative sequence with adult squint surgery at 6-12 months. The advent of the IGF-1 receptor inhibitor teprotumumab (see Tepezza infusion) has expanded medical options for active TED, but has not displaced orbital decompression as the definitive intervention for fibrotic-stage disabling proptosis or sight-threatening optic neuropathy.
Orbital decompression vs other TED interventions
Thyroid eye disease is managed in phases. The active inflammatory phase is typically treated medically (smoking cessation, selenium, intravenous glucocorticoids, teprotumumab where indicated and licensed); the inactive fibrotic phase is treated surgically with the staged rehabilitative sequence of decompression, strabismus correction and eyelid repositioning. Orbital decompression is the appropriate first step in the surgical phase and the urgent intervention in sight-threatening dysthyroid optic neuropathy.
| Intervention | Mechanism | Best for | Key trade-off |
|---|---|---|---|
| Orbital decompression (this page) | Bony wall removal (and selective fat removal) to expand orbital volume into the sinuses or temporal fossa | Sight-threatening DON; fibrotic-phase disabling proptosis, exposure keratopathy, globe subluxation | Major orbital surgery; new or worsened diplopia in 15-30 percent often requiring later strabismus surgery |
| High-dose IV glucocorticoids | Pulsed methylprednisolone to suppress active inflammatory orbitopathy | Active inflammatory TED with high CAS and progressive proptosis or threatened DON | Systemic steroid morbidity; does not reverse fibrotic-stage proptosis |
| Teprotumumab (Tepezza) | IGF-1 receptor inhibitor monoclonal antibody for active TED | Active moderate-to-severe TED with proptosis and diplopia not adequately controlled by steroids | 8-infusion course; high cost; class-specific adverse event profile; not a replacement for decompression in fibrotic-stage disease |
| Orbital radiotherapy | Low-dose external beam radiotherapy to the orbit to suppress active inflammatory disease | Active TED with motility restriction, adjunctive to steroid | Variable effect on proptosis; specific cautions in diabetes and younger patients |
| Adult squint surgery · blepharoplasty · ptosis | Stage 2 (strabismus) and stage 3 (eyelid) rehabilitation after decompression | Post-decompression diplopia, eyelid retraction, proptotic eyelid appearance | Must follow, not precede, decompression to avoid undoing prior eyelid or motility work |
See the oculoplastics treatment hub, the entropion eyelid surgery page for related lower eyelid corrective work and the endoscopic DCR page for related endoscopic orbital and lacrimal surgery.
Are you a candidate for orbital decompression?
Good candidates
- Sight-threatening dysthyroid optic neuropathy unresponsive to high-dose intravenous glucocorticoid therapy within an appropriate timeframe - an urgent surgical decompression indication.
- Inactive fibrotic-phase TED (Clinical Activity Score below 3 for at least 3-6 months) with stable thyroid function and proptosis or exposure keratopathy or chronic globe subluxation that has not responded to medical therapy.
- Severe exposure keratopathy with persistent ocular surface breakdown despite intensive lubrication and lid measures.
- Disabling cosmetic or functional proptosis with documented psychological and functional impact in a patient who has completed the active phase of TED and who has been counselled on the sequence and trade-offs.
- Chronic recurrent globe subluxation, where the eye intermittently herniates anterior to the eyelids.
Better suited to other options
- Active inflammatory phase TED without sight-threatening optic neuropathy - medical management with high-dose intravenous glucocorticoids, smoking cessation, selenium and (where indicated and licensed) teprotumumab is preferred first.
- Unstable thyroid function (recent diagnosis, recent treatment, fluctuating TSH or free T4) - stabilise endocrine status first.
- Patients who continue to smoke - smoking is the single strongest driver of poor TED outcomes and decompression in active smokers carries a worse prognosis.
- Patients whose principal problem is eyelid retraction or strabismus alone - those are stage 3 and stage 2 of the rehabilitative sequence and may not need a decompression step at all.
- Patients with significant comorbidity (uncontrolled diabetes, severe cardiac or respiratory disease) that would preclude safe general anaesthesia and a 1-2 night inpatient stay.
NHS vs private orbital decompression in the UK
Sight-threatening dysthyroid optic neuropathy is treated as an emergency in NHS specialist centres (typically London, Birmingham, Manchester, Bristol, Edinburgh and Glasgow) and is commissioned. Rehabilitative orbital decompression for fibrotic-stage proptosis, severe exposure keratopathy and chronic globe subluxation is also NHS-commissioned but is typically subject to longer waiting times and is often performed only after a documented response (or non-response) to medical therapy. Private orbital decompression offers same-week consultant continuity, multidisciplinary planning with the endocrine and ENT skull-base teams, dedicated orbital CT and MRI, surgery within weeks, a CQC-regulated inpatient stay and a structured 12-month rehabilitative pathway integrated with adult squint and eyelid surgery. See the wider oculoplastics service and the treatments hub.
Insurance and funding
Orbital decompression for thyroid eye disease is a medically-indicated procedure and is typically covered by UK private medical insurers when performed for sight-threatening dysthyroid optic neuropathy, severe exposure keratopathy, chronic globe subluxation and disabling fibrotic-phase proptosis. Pre-authorisation through the insurer is essential and the clinic will support the medical-necessity documentation. See insured patients for how we work with major UK insurers, and finance for self-pay stage payment options across the staged rehabilitative pathway.
Risks and limitations of orbital decompression
Orbital decompression is major orbital surgery and carries specific risks that are discussed in detail at consent. The most clinically significant late effect is new or worsened postoperative diplopia, reported in approximately 15-30 percent of cases overall and lower with balanced two-wall medial + lateral approaches than with older isolated inferomedial decompression; this is managed within the planned three-stage rehabilitative sequence with adult squint surgery at 6-12 months. Other recognised risks include infraorbital nerve hypoesthesia from inferior wall work, transient or persistent sinusitis from medial wall ethmoidectomy, very rare cerebrospinal fluid leak from skull-base proximity in endoscopic medial decompression, postoperative epistaxis, orbital haemorrhage, retrobulbar haematoma with the very rare possibility of acute visual loss requiring urgent decompression, infection, asymmetric proptosis reduction, and very rarely permanent visual loss. The first 24-48 hours include hourly vision, pupil and orbital pressure observation in the inpatient setting precisely so that the rare retrobulbar haematoma is recognised and decompressed before sight loss occurs. Smoking cessation, controlled thyroid function and definitive treatment of active inflammatory phase before elective decompression are the three biggest modifiable determinants of outcome.
Recovery timeline after orbital decompression
First 24-48 hours (inpatient)
Inpatient stay of 1-2 nights with hourly nursing observation of vision, pupils and orbital pressure. Cold packs, head elevation, analgesia, and a postoperative antibiotic course. Significant periorbital swelling and bruising are normal.
Weeks 1-2
Swelling and bruising peak around day 2-3 and start to settle by the end of week 2. A 1-2 week consultant review confirms wound healing, IOP, motility and the early proptosis reduction. Most patients return to non-strenuous work in weeks 2-3.
Weeks 4-12
Bony healing settles. Hertel exophthalmometry, motility and visual fields are re-checked at 6 weeks and 12 weeks. Any new or worsened postoperative diplopia is documented and an orthoptic re-measurement at 3-6 months guides the planned strabismus stage.
6-12 months
Stable proptosis reduction and motility status are confirmed at the 6-month and 12-month reviews. Adult squint surgery is scheduled where required, followed by eyelid surgery as stage 3 of the rehabilitative sequence.
How to choose a UK orbital decompression clinic
- Confirm the operating consultant is a GMC-registered oculoplastic and orbital surgeon (FRCOphth, oculoplastic fellowship) with a personal TED orbital decompression practice and an established multidisciplinary endocrine and ENT skull-base team.
- Insist on a balanced two-wall (medial + lateral) decompression as the default rehabilitative approach, not an older isolated inferomedial decompression, to minimise new-onset postoperative diplopia.
- Ask about a same-week pathway for sight-threatening dysthyroid optic neuropathy with same-week endoscopic medial wall decompression where indicated.
- Ask for the surgeon's personal proptosis reduction, new-diplopia rate, complication rate and re-operation rate.
- Confirm the clinic offers the full three-stage rehabilitative sequence in-house: decompression, then adult squint surgery, then blepharoplasty and ptosis correction as needed.
- Insist on a CQC-regulated UK private hospital with a 1-2 night inpatient capability, 24-hour orbital observation and an emergency retrobulbar haematoma decompression pathway.
- Insist on a written, itemised quote covering the consultant assessment, multidisciplinary planning, orbital CT and MRI, anaesthetic and theatre fees, prosthetic implants where used, inpatient stay and the 12-month rehabilitative follow-up.
See our consultant oculoplastic surgeon team and the treatments hub for the wider offering.
Orbital decompression frequently asked questions
How much does private orbital decompression cost in the UK in 2026?
Self-pay orbital decompression in the UK in 2026 is typically GBP 7,500-12,000 unilateral, GBP 12,000-18,000 bilateral two-wall and GBP 15,000-22,000 bilateral three-wall with fat removal, inclusive of consultant assessment, multidisciplinary planning, orbital CT and MRI, anaesthetic and theatre fees, prosthetic implants where used, the inpatient stay and a 12-month follow-up programme aligned with the staged rehabilitative pathway.
Is orbital decompression available on the NHS?
Yes. Sight-threatening dysthyroid optic neuropathy is treated as an emergency in NHS specialist centres and rehabilitative orbital decompression for fibrotic-stage proptosis and exposure keratopathy is also commissioned, although waiting times are typically longer and access is often subject to documented response to medical therapy first.
When is orbital decompression an emergency?
Sight-threatening dysthyroid optic neuropathy - where the optic nerve is compressed at the orbital apex by enlarged extraocular muscles and visual acuity, colour vision or visual field is dropping - is a sight-saving emergency. If high-dose intravenous glucocorticoid therapy fails to restore function within an appropriate timeframe, urgent endoscopic medial wall and apical decompression is performed within days.
How much proptosis reduction will I get?
A balanced two-wall (medial + lateral) decompression typically reduces proptosis by approximately 3-5 mm per side. A three-wall decompression with selective fat removal can achieve 5-7 mm or more. The actual reduction is calibrated at preoperative planning against the Hertel exophthalmometer reading and the underlying orbital CT.
Will orbital decompression cause double vision?
New or worsened postoperative diplopia is the most clinically significant late effect, reported in approximately 15-30 percent of cases overall. Modern balanced two-wall medial + lateral decompression has lower rates than older isolated inferomedial approaches. New-onset diplopia is managed within the staged rehabilitative pathway with adult squint surgery at 6-12 months.
Will I need strabismus or eyelid surgery as well?
Often, yes. Orbital decompression is the first step of the established three-stage rehabilitative sequence in thyroid eye disease: decompression first, then strabismus surgery for any pre-existing or new diplopia, then eyelid surgery to correct retraction or proptotic eyelid appearance. The clinic offers all three stages in-house.
How long is the inpatient stay?
Typical inpatient stay is 1-2 nights for bilateral decompression with hourly nursing observation of vision, pupils and orbital pressure in the first 24-48 hours to detect the very rare retrobulbar haematoma early.
How does orbital decompression compare with Tepezza (teprotumumab)?
Tepezza is an IGF-1 receptor inhibitor monoclonal antibody for active TED that can reduce proptosis and diplopia during the active inflammatory phase. Orbital decompression is the surgical answer in fibrotic-stage disease and the urgent intervention for sight-threatening dysthyroid optic neuropathy. The two treatments target different phases of the same disease and are complementary, not mutually exclusive; many patients receive medical therapy first and decompression later if proptosis remains disabling.
Do I have to stop smoking before orbital decompression?
Yes. Smoking is the single strongest modifiable driver of poor outcomes in thyroid eye disease and decompression in active smokers carries a significantly worse prognosis. Smoking cessation is mandatory before elective decompression, and is the most important non-surgical intervention any TED patient can make at any disease stage.
Do I have to have stable thyroid function first?
Yes for elective rehabilitative decompression. Endocrine status should be stabilised by the endocrine team (TSH and free T4 in target range, ideally for 3-6 months) before elective surgery. The only exception is sight-threatening dysthyroid optic neuropathy, where urgent decompression is performed regardless of thyroid status.
What are the risks of orbital decompression?
Specific risks include new or worsened diplopia (15-30 percent), infraorbital nerve hypoesthesia from inferior wall work, transient or persistent sinusitis, very rare cerebrospinal fluid leak from endoscopic medial decompression, epistaxis, orbital haemorrhage, retrobulbar haematoma with very rare acute visual loss requiring urgent decompression, infection, asymmetric proptosis reduction and very rarely permanent visual loss. The 24-48 hour inpatient observation is designed precisely to catch the rare retrobulbar haematoma early.
When can I return to work and exercise after orbital decompression?
Most patients return to non-strenuous office work in weeks 2-3. Strenuous exercise, contact sports and heavy lifting are typically avoided for 4-6 weeks. Air travel is permitted from week 2-3. Specific guidance depends on the approach used and your healing at the consultant reviews.
Where can I book a private orbital decompression consultation in the UK?
Book a free online consultation or an in-person assessment with our consultant oculoplastic team through the eyesurgeryclinic.co.uk booking pages or call 0800 852 7782 to be triaged the same week and to confirm current availability for elective and (where applicable) urgent same-week dysthyroid optic neuropathy pathways.
Methodology and sources
Pricing is taken from a 2026 UK private oculoplastic and orbital tariff audit across CQC-regulated providers with a multidisciplinary endocrine and ENT skull-base team and is presented as a typical self-pay range per side and per approach, inclusive of consultant assessment, multidisciplinary planning, orbital CT and MRI, anaesthetic and theatre fees, prosthetic implants where used, the inpatient stay and a 12-month rehabilitative follow-up. Clinical statements are drawn from EUGOGO (European Group on Graves' Orbitopathy) consensus statements and management guidelines, Royal College of Ophthalmologists thyroid eye disease guidance, NICE guidance on teprotumumab and dysthyroid optic neuropathy management, prospective UK and international cohort and randomised comparative studies on approach selection and outcomes, peer-reviewed work in Ophthalmic Plastic and Reconstructive Surgery, Eye, the British Journal of Ophthalmology and Ophthalmology, and ENT/skull-base society guidance on endoscopic transethmoidal orbital decompression. Page last reviewed 28 May 2026 against the live URL set on eyesurgeryclinic.co.uk.
Book a consultant orbital decompression assessment
Find out whether orbital decompression is the right option for your thyroid eye disease with a same-week consultant oculoplastic appointment, full orbital assessment, planned multidisciplinary endocrine and ENT review and a transparent UK 2026 quote.
Or call 0800 852 7782.
Back to Treatments